Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. (5th March 2014)

• Record Type: Journal Article
• Authors: Beebe‐Dimmer, Jennifer L.; Isaacs, William B.; Zuhlke, Kimberly A.; Yee, Cecilia; Walsh, Patrick C.; Isaacs, Sarah D.; Johnson, Anna M.; Ewing, Charles E.; Humphreys, Elizabeth B.; Chowdhury, Wasim H.; Montie, James E.; Cooney, Kathleen A.
• Is Part Of: BJU international. Volume 113:Number 5(2014:May)
• Page Start: 830
• Page End: 835
• Publication Date: 2014-03-05
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12522
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12522-sec-0001" sec-type="section"> <title>Objective</title> <p> <list id="bju12522-list-0001" list-type="bullet"> <list-item> <p>To determine the prevalence and clinical correlates of the G84E mutation in the homeobox transcription factor, or <italic>HOXB13</italic>, gene using DNA samples from 9559 men with prostate cancer undergoing radical prostatectomy.</p> </list-item> </list> </p> </sec> <sec id="bju12522-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p> <list id="bju12522-list-0002" list-type="bullet"> <list-item> <p>DNA samples from men treated with radical prostatectomy at the University of Michigan and John Hopkins University were genotyped for G84E and this was confirmed by Sanger sequencing.</p> </list-item> <list-item> <p>The frequency and distribution of this allele was determined according to specific patient characteristics (family history, age at diagnosis, pathological Gleason grade and stage).</p> </list-item> </list> </p> </sec> <sec id="bju12522-sec-0003" sec-type="section"> <title>Results</title> <p> <list id="bju12522-list-0003" list-type="bullet"> <list-item> <p>Of 9559 patients, 128 (1.3%) were heterozygous carriers of G84E.</p> </list-item> <list-item> <p>Patients who possessed the variant were more likely to have a family history of prostate cancer than those who did not (46.0 vs 35.4%; <italic>P</italic> = 0.006).</p> </list-item> <list-item> <p>G84E carriers were also more likely to be diagnosed at a younger age than non‐carriers (55.2 years vs 58.1 years; <italic>P</italic> < 0.001).</p> </list-item> <list-item> <p>No difference in the proportion of patients diagnosed with high grade or advanced stage tumours according to carrier status was observed.</p> </list-item> </list> </p> </sec> <sec id="bju12522-sec-0004" sec-type="section"> <title>Conclusions</title> <p> <list id="bju12522-list-0004" list-type="bullet"> <list-item> <p>In the present study, carriers of the rare G84E variant in <italic>HOXB13</italic> were both younger at the time of diagnosis and more likely to have a family history of prostate cancer compared with homozygotes for the wild‐type allele.</p> </list-item> <list-item> <p>No significant differences in allele frequency were detected according to selected clinical characteristics of prostate cancer.</p> </list-item> <list-item> <p>Further investigation is required to evaluate the role of <italic>HOXB13</italic> in prostate carcinogenesis.</p> </list-item> </list> </p> </sec> </abstract>